https://scholars.lib.ntu.edu.tw/handle/123456789/487351
標題: | Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma | 作者: | CHIA-CHI LIN CHIH-HUNG HSU CHAO-YUAN HUANG ANN-LII CHENG Vogelzang N.J. YEONG-SHIAU PU |
公開日期: | 2007 | 卷: | 177 | 期: | 1 | 起(迄)頁: | 84-89 | 來源出版物: | Journal of Urology | 摘要: | Purpose: Conventional chemotherapy for urothelial carcinoma, such as methotrexate, vinblastine, doxorubicin and cisplatin, is associated with significant toxicity. We have previously reported a low toxicity and yet moderately active regimen containing weekly infusional cisplatin and high dose 5-fluorouracil/leucovorin for advanced urothelial carcinoma. We tested the efficacy and toxicity of adding paclitaxel to that regimen. Materials and Methods: Between April 2000 and December 2004, 44 patients with a median age of 66 years with metastatic urothelial carcinoma were enrolled. The paclitaxel, cisplatin and high dose 5-fluorouracil/leucovorin regimen consisted of 70 mg/m2 paclitaxel daily as a 1-hour infusion on days 1 and 8, 35 mg/m2 cisplatin daily as a 24-hour infusion on days 2 and 9, 2,000 mg/m2 5-fluorouracil daily and 300 mg/m2 leucovorin daily as a 24-hour infusion on days 2 and 9. The cycles repeated every 21 days. A total of 25 patients (64%) had a creatinine clearance of 35 to 60 ml per minute. Results: A total of 210 cycles (mean 4.8 per patient) were administered. Of the 40 patients eligible for response evaluation 11 (28%) and 19 (48%) were complete and partial responders with an overall response rate of 75% (95% CI 61 to 89). Median overall and progression-free survival in the whole group was 17.0 (95% CI 13.7 to 20.3) and 8.3 months (95% CI 6.4 to 10.2), respectively. Two-year disease-free survival was 15%. Grade 3 or 4 anemia, leukopenia and thrombocytopenia occurred at 23, 30 and 12 cycles, respectively. Nonhematological toxicity included infection, vomiting and diarrhea, etc. There were 2 treatment related deaths. Conclusions: Paclitaxel, cisplatin and high dose 5-fluorouracil/leucovorin is an active regimen against metastatic urothelial carcinoma which has an acceptable toxicity profile. ? 2007 American Urological Association. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845342862&doi=10.1016%2fj.juro.2006.08.058&partnerID=40&md5=485d5bdaa6426d9a22cbd7f9b8e355b2 https://scholars.lib.ntu.edu.tw/handle/123456789/487351 |
ISSN: | 0022-5347 | DOI: | 10.1016/j.juro.2006.08.058 | SDG/關鍵字: | antiemetic agent; betamethasone; cisplatin; creatinine; diphenhydramine; fluorouracil; folinic acid; paclitaxel; ranitidine; adult; aged; alopecia; anemia; article; bone marrow toxicity; cancer combination chemotherapy; cancer survival; chemotherapy induced emesis; clinical trial; combination chemotherapy; confidence interval; continuous infusion; controlled clinical trial; controlled study; creatinine clearance; creatinine urine level; diarrhea; disease free survival; drug dose escalation; drug dose reduction; drug efficacy; drug fatality; drug fever; drug infusion; drug megadose; drug safety; drug withdrawal; febrile neutropenia; female; human; infection; leukopenia; liver toxicity; male; metastatic urothelial carcinoma; multiple cycle treatment; nausea; nephrotoxicity; neurotoxicity; neutropenia; phase 2 clinical trial; pneumonia; priority journal; side effect; stomatitis; survival time; thrombocytopenia; treatment outcome; treatment response; urogenital tract cancer; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Vitamin B Complex |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。